AlzBiomarker
Alzheimer's Disease vs Control: Aβ42 (CSF)
Most studies over the past 25 years have consistently found lower levels of Aβ42 in the cerebrospinal fluid of people with Alzheimer’s disease than in controls. In general, levels in the AD group are approximately half of control levels. Meta-analysis of more than 200 comparisons yielded an effect size of 0.552 (p <0.0001). The decrease in Aβ42 in the CSF of AD patients is thought to reflect the deposition of the peptide into amyloid plaques in the brain.
Loading data...